$1.22 EPS Expected for Zoetis Inc. (NYSE:ZTS) This Quarter

Wall Street analysts predict that Zoetis Inc. (NYSE:ZTSGet Rating) will report earnings per share of $1.22 for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Zoetis’ earnings, with the lowest EPS estimate coming in at $1.11 and the highest estimate coming in at $1.29. Zoetis posted earnings per share of $1.26 in the same quarter last year, which would suggest a negative year-over-year growth rate of 3.2%. The firm is scheduled to report its next earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Zoetis will report full year earnings of $5.14 per share for the current financial year, with EPS estimates ranging from $5.09 to $5.20. For the next financial year, analysts expect that the company will post earnings of $5.85 per share, with EPS estimates ranging from $5.67 to $6.03. Zacks’ EPS calculations are an average based on a survey of research analysts that follow Zoetis.

Zoetis (NYSE:ZTSGet Rating) last posted its quarterly earnings results on Tuesday, February 15th. The company reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.04. Zoetis had a net margin of 26.20% and a return on equity of 50.71%. The firm had revenue of $1.97 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same period in the prior year, the firm posted $0.91 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year.

A number of research analysts have recently commented on ZTS shares. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $242.00 price objective for the company. in a research report on Saturday, January 8th. Citigroup decreased their price objective on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research report on Wednesday, March 9th. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 26th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $224.78.

Shares of ZTS traded down $6.64 during midday trading on Monday, reaching $174.67. The stock had a trading volume of 3,510,546 shares, compared to its average volume of 2,466,568. The firm has a 50 day simple moving average of $189.31 and a 200-day simple moving average of $206.20. Zoetis has a one year low of $165.22 and a one year high of $249.27. The firm has a market cap of $82.41 billion, a PE ratio of 40.82, a P/E/G ratio of 3.01 and a beta of 0.77. The company has a current ratio of 3.86, a quick ratio of 2.79 and a debt-to-equity ratio of 1.45.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 1st. Investors of record on Thursday, April 21st will be issued a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Wednesday, April 20th. Zoetis’s payout ratio is 30.45%.

In other Zoetis news, CEO Kristin C. Peck sold 10,000 shares of Zoetis stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $192.29, for a total value of $1,922,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 2,065 shares of the business’s stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $196.54, for a total transaction of $405,855.10. The disclosure for this sale can be found here. Insiders sold a total of 52,622 shares of company stock valued at $9,995,351 in the last quarter. Corporate insiders own 0.12% of the company’s stock.

Large investors have recently modified their holdings of the company. Investment Research & Advisory Group Inc. acquired a new position in shares of Zoetis in the 4th quarter valued at approximately $26,000. Account Management LLC acquired a new position in shares of Zoetis in the 4th quarter valued at approximately $2,715,000. Amplius Wealth Advisors LLC acquired a new position in shares of Zoetis in the 4th quarter valued at approximately $31,000. Aquire Wealth Advisors LLC bought a new stake in shares of Zoetis during the 4th quarter valued at approximately $32,000. Finally, Consolidated Planning Corp bought a new stake in shares of Zoetis during the 3rd quarter valued at approximately $28,000. Institutional investors own 90.73% of the company’s stock.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Articles

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.